Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-05-04
2009-11-03
Tsang, Cecilia (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C514S002600, C514S014800, C424S001690, C424S093200
Reexamination Certificate
active
07612164
ABSTRACT:
This invention relates to polypeptides which affect myocardial cell differentiation and organisation of cardiac muscle contractile units, assay for identifying such polypeptides, and methods for improving cardiac function by the administration of such polypeptides to patients with heart disease. In one aspect, the invention provides a therapeutic composition comprising a peptide consisting of a fragment of human neuregulin β2 isoform containing the EGF-like domain, e.g., SEQ ID NO.:2, and a physiologically acceptable carrier, excipient or stabilizer.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4485045 (1984-11-01), Regen
patent: 4496689 (1985-01-01), Mitra
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5530109 (1996-06-01), Goodearl et al.
patent: 5586110 (1996-12-01), Nakaki et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5667780 (1997-09-01), Ho et al.
patent: 5714385 (1998-02-01), Mather et al.
patent: 5716930 (1998-02-01), Goodearl et al.
patent: 5721139 (1998-02-01), Mather et al.
patent: 5834229 (1998-11-01), Vandlen et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5859206 (1999-01-01), Vandlen et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6033660 (2000-03-01), Mather et al.
patent: 6087323 (2000-07-01), Gwynne et al.
patent: 6096873 (2000-08-01), Schaefer et al.
patent: 6121415 (2000-09-01), Godowski et al.
patent: 6136558 (2000-10-01), Ballinger et al.
patent: 6156728 (2000-12-01), Gao et al.
patent: 6162641 (2000-12-01), Goldman et al.
patent: 6169070 (2001-01-01), Chen et al.
patent: 6252051 (2001-06-01), Godowski et al.
patent: 6387638 (2002-05-01), Ballinger et al.
patent: 6399746 (2002-06-01), Vandlen et al.
patent: 6444642 (2002-09-01), Skylar et al.
patent: 6446242 (2002-09-01), Lien et al.
patent: 6593290 (2003-07-01), Gao et al.
patent: 6635249 (2003-10-01), Marchionni et al.
patent: 6750196 (2004-06-01), Reh et al.
patent: 7226907 (2007-06-01), Zhou
patent: 2006/0019888 (2006-01-01), Zhou
patent: 2006/0194734 (2006-08-01), Zhou
patent: 2006/0199767 (2006-09-01), Zhou
patent: 2007/0129296 (2007-06-01), Zhou
patent: 2007/0213264 (2007-09-01), Zhou
patent: 68278/94 (1994-12-01), None
patent: 1498656 (2004-05-01), None
patent: 1138785 (2004-12-01), None
patent: 3218121 (1983-11-01), None
patent: 0 036 676 (1981-09-01), None
patent: 0 052 322 (1982-05-01), None
patent: 0 058 481 (1982-08-01), None
patent: 0 088 046 (1983-09-01), None
patent: 0 102 324 (1984-03-01), None
patent: 0 143 949 (1985-06-01), None
patent: 0 133 988 (1995-03-01), None
patent: 0 647 449 (1995-04-01), None
patent: 0 142 641 (1995-05-01), None
patent: 60007934 (1985-01-01), None
patent: WO 89/01489 (1989-02-01), None
patent: WO 92/18627 (1992-10-01), None
patent: WO 94/00140 (1994-01-01), None
patent: WO 94/26298 (1994-11-01), None
patent: WO 95/32724 (1995-12-01), None
patent: WO 96/15812 (1996-05-01), None
patent: WO 97/09425 (1997-03-01), None
patent: WO 99/18976 (1999-04-01), None
patent: WO 00/37095 (2000-06-01), None
patent: WO 03/099300 (2003-12-01), None
patent: WO 03/099320 (2003-12-01), None
patent: WO 03/099321 (2003-12-01), None
Balligand, et al., “Cardiac endothelium and tissue growth,” Prog Cardiovasc Dis. Jan-Feb 1997; 39(4):351-360.
Chien, et al., “Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response,” FASEB J. Dec. 1991; 5(15):3037-3046.
Colucci, et al., “Pathphysiology of heart failure,” Chapter 13 inHeart Diseases: A textbook of cardiovascular medicine, Braunwald, ed., Saunders, Philadelphia. 1996; 5:394-420.
Dias, et al., “The molecular basis of skeletal muscle differentiation,” Semin Diagn Pathol. Feb. 1994; 11(1):3-14.
Eppstein, et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,”Proc Natl Acad Sci U S A. Jun. 1985; 82(11):3688-3692.
Florini-Jr., et al., “Stimulation of myogenic differentiation by a neuregulin, glial growth factor 2,” J Biol Chem. May 31,1996; 271(22):12699-12702.
Holmes, et al., “Identification of heregulin, a specific activator of p185erbB2,” Science. May 22, 1992; 256(5060): 1205-1210.
Hwang, et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proc Natl Acad Sci U S A. Jul. 1980; 77(7):4030-4034.
Langer, et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J Biomed Mater Res. Mar. 1981; 15(2):267-277.
Parker, et al., “p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells,” Science. Feb. 17, 1995; 267(5200):1024-1027.
Physicians' Desk Reference. Medical Economics Data Production Co., Montvale, NJ. 1994; pp. 2314-2320.
Rumyantsev, “Interrelations of the proliferation and differentiation processes during cardiac myogenesis and regeneration,” Int Rev Cytol. 1977; 51:186-273.
Sidman, et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers. Jan. 1983; 22(1):547-556.
Simpson, et al., “Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines,” Circ Res. Dec. 1982; 51(6):787-801.
Zhao, et al., “Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes,” J Biol Chem. Apr. 24, 1998; 273(17):10261-10269.
Zhao, et al., “Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes,” Development. May 1998; 125(10):1899-1907.
Zhou, et al., “Retinoid-dependent pathways suppress myocardial cell hypertrophy,” Proc Natl Acad Sci U S A. Aug. 1, 1995; 92(16):7391-7395.
Gray H., Crray's Anatomy: The Anatomical Basis of Medicine and Surgery, 1995, Ed. Williams et al., Churchill Livingstone, Edinburgh, pp. 264-254, 298-310 and 739-771.
International Search Report for International Application No. PCT/AU99/01137, Mar. 10, 2000.
Audet Maury
Jones Day
Tsang Cecilia
Zensun (Shanghai) Science and Technologies Ltd.
LandOfFree
Cardiac muscle function and manipulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac muscle function and manipulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac muscle function and manipulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100113